Flashpoint Announces New Joint Venture Fund Targeting $150 Million to Invest in Direct Secondaries
31.10.2023 12:27:00 EET | Business Wire | Press release
Flashpoint announces its partnership with renowned growth investor, Roman Ivaniuk through the establishment of a joint venture fund to invest in direct secondary opportunities in growth stage companies in Europe.
Flashpoint is an international tech investment manager with over $400 million AUM focused on tech companies originating from Europe and Israel. Roman Ivaniuk is an investment banker with 12+ years of experience, 50+ closed deals (VC, PE, pre-IPO, IPO), and $1B+ total closed deals value. He is a Founder and former MP of GR Capital (a Pan-European venture fund), the current Founder and MP of an investment company BrightOne Capital.
The fund’s strategy will be to support prominent growth-stage tech companies in Europe through investments in direct secondary opportunities. The unique synergy of this partnership will be directed towards raising $150 million, with an initial $50 million for the first closing. The partners have been present in the EU/Israel VC ecosystem for 10+ years. They established direct relationships with founders and investors alike, giving them unique insights into market trends and access to exclusive deal flow.
Flashpoint made 13 primary investments into growth-stage companies within its portfolio of 47 active investments. This is the second Flashpoint fund investing in direct secondaries: the predecessor, Flashpoint Secondary Fund I (“FSF I”), was launched in 2020 and was anchored by the Scheinberg family office. The current portfolio of FSF I consists of 6 later-stage companies, including K2View, Printify, Preply, Mesh Payments, Booksy, and Landtech.
Roman Ivaniuk’s track record covers investments in WeFox, McMackler, Glovo, Deliveroo, Sennder, Azimo and Flashcenpost among others. There were 10 successful exits in his portfolio in 2016-2021. He also has a strong private equity experience in Ukraine, having developed the country’s largest healthcare chain Dobrotut.
Flashpoint, led by Alex Konoplyasty, Michael Szalontay, and Igor Bilous, is renowned for its strategic investments in innovative technology startups originating from Emerging Europe and Israel. Flashpoint manages five funds: 3 VC funds, 1 Growth Debt Fund, and 1 Direct Secondaries Fund. Investors in Flashpoint’s funds include more than 130 major family offices and HNWIs. The funds have made investments in over 66 companies including Guesty, Chili Piper, and Office RnD. Flashpoint has completed fifteen exits, including the sale of its stakes in Shazam (to Apple), Chess.com (to PokerStars founders and General Atlantic), Marketman (to PSG), and Gurushots (to Zedge), Comeet (to Boathouse Capital), etc.
Currently, Roman is focused on late-stage VC and Growth investments in the EU/UK, on globalization and expansion of profitable companies with Ukrainian roots, cross-border transactions, and international fundraising.
Michael Szalontay, General Partner at Flashpoint, said: “We are delighted to announce our partnership with Roman Ivaniuk on this innovative joint venture fund. Together, we can combine our substantial networks and track records across CEE and Israel to deliver significant value and expertise to investors and investees alike. We are excited about our prospects as we pursue our goal of raising $150 million which we will allocate to some of the world’s most exciting growth stories.”
Roman Ivaniuk, Managing Partner at Flashpoint RI Secondary Fund II, said: “This joint venture is an extension of our successful investments in the EU tech companies with their further expansion. Flashpoint VC has a strong CEE base and a great VC track record. I helped to globalize my portfolio of growth companies in the CEE region and know every step from the inside. Together we have a cool overlap and unique strategy. Our expertise and direct access to the companies is a great value for our Secondary Fund. I feel confidence and excitement toward our new joint venture and our future investment opportunities.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231031982284/en/
Contact information
Maria Eliseeva
Head of PR/Marketing at Flashpoint VC
Maria.e@flashpointvc.com
+371 26380366
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 15:17:00 EEST | Press release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 15:17:00 EEST | Press release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Saildrone Unveils Spectre, a New Class of High-Speed Unmanned Surface Vessel for Naval Operations20.4.2026 15:00:00 EEST | Press release
Saildrone, the world leader and most experienced operator of unmanned surface vehicles (USVs), today released the design of the Saildrone Spectre, the culmination of two years of intense design work, leveraging over 10 years of operational USV experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420620393/en/ Two Saildrone Spectre variants are built around different mission needs: Spectre Silent Endurance (right) uses wing assist for extreme endurance and silent propulsion. Spectre Stealth Strike (left) meets all mUSV requirements. At 52 meters (170 feet) long, weighing 250 tonnes, and capable of up to 30 knots, Spectre is the largest, fastest, and most capable Saildrone platform to date. Spectre is optimized for anti-submarine warfare (ASW) operations, a mission set that demands extreme endurance and an ultra-quiet acoustic signature. Spectre achieves this by leveraging the proven endurance, reliability, and silent
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom